SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NATCO Pharma soars on receiving USFDA approval for Lansoprazole Capsules

19 Dec 2012 Evaluate

NATCO Pharma is currently trading at Rs. 492.65, up by 24.60 points or 5.26% from its previous closing of Rs. 467.40 on the BSE.

The scrip opened at Rs. 477.45 and has touched a high and low of Rs. 496.00 and Rs. 477.45 respectively. So far 50,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 496.00 on 10-Dec-2012 and a 52 week low of Rs. 223.50 on 20-Dec-2011.

Last one week high and low of the scrip stood at Rs. 476.70 and Rs. 462.00 respectively. The current market cap of the company is Rs. 1,532 crore.

The promoters holding in the company stood at 57.05% while Institutions and Non-Institutions held 17.88% and 25.07% respectively.

NATCO Pharma has received approval from the US Food & Drug Administration (USFDA), of its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed Release Capsules, USP, 15 mg and 30 mg for the prescription market. The shipments of this product will commence immediately.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.

Natco Pharma Share Price

1068.75 12.75 (1.21%)
22-Apr-2026 10:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1657.70
Dr. Reddys Lab 1213.25
Cipla 1227.75
Zydus Lifesciences 927.65
Lupin 2305.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×